The prevalence of CYP2C19 mutations in Turkish patients with dyspepsia

Turkish Journal of Gastroenterology

Volumn 20, Issue 3, 2009, Pages 161-164

  Çelebi, Altay ^a   Kocaman, Orhan ^a   Savli, Hakan ^a   Aygün, Cem ^a   Konduk, Buǧra Tolga ^a   Şentürk, Ömer ^a   Hülagu, Sadettin ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

CYP2C19*2; CYP2C19*3; Dyspepsia; Turkish patients

Indexed keywords

CYTOCHROME P450 2C19; DNA;

ADULT; ALLELE; ARTICLE; DNA ISOLATION; DYSPEPSIA; FEMALE; GENOTYPE; HETEROZYGOTE DETECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; ARYL HYDROCARBON HYDROXYLASES; DYSPEPSIA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; TURKEY; YOUNG ADULT;

EID: 70350145458     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: 10.4318/tjg.2009.0001     Document Type: Article

References (11)

1. Goldstein JA. Clinical relevance of genetic polymorphism in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349-355
2. Dickson EJ, Stuart RC. Genetics of response to proton pump inhibitor therapy. Am J Pharmacogenomics 2003; 3: 303-315
3. Rosemary J, Adithan C, Padmaja N, et al. The effect of the CYP2C19 genotype on the hydroxylation index of omeprazole in South Indians. Eur J Clin Pharmacol 2005; 61: 19-23. (Pubitemid 40558275)
4. Van Zanten SV, Thompson K. Should the presence of polymorphisms of CYP2C19 enzymes influence the choice of the proton pump inhibitor for treatment of Helicobacter pylori infection? Am J Gastroenterol 2006; 101: 1476-1478
5. Drossman DA. Rome III: the new criteria. Chin J Dig Dis 2006; 7: 181-185
6. Chong E, Ensom M. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003; 23: 460-471 (Pubitemid 36384325)
7. Talley NJ, Vakil N. Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005; 100: 2324-2337
8. Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1- week triple therapies. Gastroenterology 1999; 116: 248-253 (Pubitemid 29055345)
9. Talley NJ. Therapeutic options in nonulcer dyspepsia. J Clin Gastroenterol 2001; 32: 286-293
10. Tanum L, Malt UF. A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind place-bo- controlled study with Mianserin. Scand J Gastroenterol 1996; 31: 318-325 (Pubitemid 26117753)
11. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9: 442-473 (Pubitemid 38903502)